Nuclear peroxisome proliferator-activated receptors and thiazolidinediones

International Anesthesiology Clinics

Volumn 43, Issue 2, 2005, Pages 1-21

  Grinberg, Achikam ^a   Park, Kyung W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BEZAFIBRATE; C REACTIVE PROTEIN; CD40 LIGAND; CELL NUCLEUS RECEPTOR; CHOLESTEROL; CIPROFIBRATE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; FATTY ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSANOID; INSULIN; INTERLEUKIN 6; LEUKOTRIENE B4; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; NATRIURETIC FACTOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROSTAGLANDIN; RESISTIN; ROSIGLITAZONE; STRESS ACTIVATED PROTEIN KINASE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; TROGLITAZONE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

ADIPOCYTE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DILATATION; DIABETES CONTROL; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DYSLIPIDEMIA; GENE EXPRESSION REGULATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART FAILURE; HEART INFARCTION SIZE; HEART PROTECTION; HUMAN; HYPERTENSION; INCIDENCE; INOTROPISM; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; LIPID METABOLISM; LIVER TOXICITY; MACROPHAGE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REPERFUSION INJURY; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM; WEIGHT GAIN;

ANESTHESIA; ANIMALS; ANTILIPEMIC AGENTS; HUMANS; HYPOGLYCEMIC AGENTS; METABOLIC SYNDROME X; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; THIAZOLIDINEDIONES;

EID: 17644400114     PISSN: 00205907     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aia.0000157485.91241.0b     Document Type: Review

References (161)

1. Must A, Spadano J, Coakley EH. The disease burden associated with overweight and obesity. JAMA. 199;282:1523-1529.
2. Pi-Sunyer FX. Health implications of obesity. Am J Clin Nutr. 1991;53:1595S-1603S.
3. National DM Fact Sheet: General Information and National Estimates on DM in the United States. Atlanta: Centers for Disease Control and Prevention; 2000.
4. The Burden of Chronic Diseases and Their Risk Factors. National and State Perspectives. US Dept of Health and Human Services, Centers for Disease Control and Prevention; February 2002.
5. WHO web site. Available at: http://www.who.int/dietphysicalactivity/ publications/facts/obesity/en/. Accessed November 11, 2004.
6. Surgeon General's web site. Available at: http://www.surgeongeneral.gov/ topics/obesity/calltoaction/factsheet02.pdf. Accessed November 19, 2004.
7. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, DM, and obesity-related health risk factors, 2001. JAMA. 2003;289:76-79.
8. Park Y-W, Zhu S, Palaniappan L, et al. The metabolic syndrome; prevalence and associated risk factor findings in the US population from the third national health and nutrition examination survey, 1988-1994. Arch Intern Med. 2003;163:427-436.
9. Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without c-reactive protein as a predictor of coronary heart disease and diabetes in the west of Scotland coronary prevention study. Circulation. 2003;108:414-419.
10. Third report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). National cholesterol education program. National Heart, Lung, and Blood Institute, National Institutes of Health. NIH Publication No. 02-5215. September 2002.
11. Després J-P. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition. 1993;9:452-459.
12. Bjorntorp P. Body fat distribution, insulin resistance, and metabolic diseases. Nutrition. 1997;13:795-803.
13. Okosun IS, Liao Y, Rotimi CN, et al. Abdominal adiposity and clustering of multiple metabolic syndrome in white, black and Hispanic Americans. Ann Epidemiol. 2000;10: 263-270.
14. Bjorntorp P. Abdominal obesity and the metabolic syndrome. Ann Med. 1992;24:465-468.
15. Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease: west of Scotland Coronary Prevention Study Group. N Engl J Med. 2000;343:1148-1155.
16. Freeman DJ, Norrie J, Caslarke MJ, et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes. 2002;51:1596-1600.
17. Ham TS, Williams K, Sattar N, et al. Prospective analysis of obesity, body fat distribution and hyperinsulinaemia in the development of metabolic syndrome in the San Antonio Heart Study. Obes Res. 2002;10:923-931.
18. Sattar N, Tan CE, Han T, et al. Association of indices of adiposity with the atherogenic lipoprotein profile. Int J Obes. 1998;22:432-439.
19. Wei M, Gaskill SP, Haffner SM, et al. Waist circumference as the best predictor of noninsulin dependent diabetes mellitus (NIDDM) compared to body mass index, waist/hip ratio and other anthropometric measurements in Mexican Americans: a 70 year prospective study. Obes Res. 1997;5:16-23.
20. Stevens J, Couper D, Pankow J, et al. Sensitivity and specificity on anthropometrics for the prediction of DM in a biracial cohort. Obes Res. 2001;9:696-705.
21. Rexrode KM, Buring JE, Manson JE. Abdominal and total adiposity and risk of coronary heart disease in men. Int J Obes. 2001;25:1047-1056.
22. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk if incident cardiovascular event: an-8-year follow-up of 14,719 initially healthy American women. Circulation. 2003;107:391-397.
23. Mekki N, Christofilis MA, Charbonnier M, et al. Influence of obesity and body fat distribution on postprandial lipemia and triglyceride-rich lipoproteins in adult women. J Clin Endocrinol Metab. 1999;84:184-191.
24. Bodkin NL, Hannah JS, Ortmeyer HK, et al. Central obesity in rhesus monkeys: association with hyperinsulinemia, insulin resistance and hypertriglyceridemia? Int J Obes. 1993;17:53-61.
25. Julien P, Vohl M-C, Gaudet D, et al. Hyperinsulinemia and abdominal obesity affect the expression of hypertriglyceridemia in heterozygous familial lipoprotein lipase deficiency. Diabetes. 1997;46:2063-2068.
26. Phillips NR, Havel RJ, Kane JP. Levels and interrelationships of serum and lipoprotein cholesterol and triglycerides: association with adiposity and the consumption of ethanol, tobacco, and beverages containing caffeine. Arteriosclerosis. 1981;1:13-24.
27. Schaefer EJ, McNamara JR, Genest J Jr, et al. Clinical significance of hypertriglyceridemia. Semin Thromb Hemost. 1988;14:143-148.
28. Karhapää P, Malkki M, Laakso M. Isolated low HDL cholesterol: an insulin-resistant state. Diabetes. 1994;43:411-417.
29. Nilsson PM, Lind L, Pollare T, et al. Differences in insulin sensitivity and risk markers due to gender and age in hypertensives. J Hum Hypertens. 2000;14:51-56.
30. Vanhala MJ, Kumpusalo EA, Pitkäjarvi TK, et al. Hyperinsulinemia and clustering of cardiovascular risk factors in middle-aged hypertensive Finnish men and women. J Hypertens. 1997;15:475-481.
31. Tripathy D, Carlsson M, Almgren P, et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes. 2000;49:975-980.
32. Haffner SM, Miettinen H, Gaskill SP, et al. Decreased insulin action and insulin secretion predict the development of impaired glucose tolerance. Diabetologia. 1996; 39:1201-1207.
33. Edelstein SL, Knowler WC, Bain RP, et al. Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes. 1997;46: 701-710.
34. Lindahl B, Weinehall L, Asplund K, et al. Screening for impaired glucose tolerance: results from a population-based study in 21,057 individuals. Diabetes Care. 1999;22: 1988-1992.
35. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
36. National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults-The Evidence Report. NIH Publication No. 98 4083. Bethesda, MD: National Heart, Lung and Blood Institute; 1998.
37. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults-the evidence report. Obes Res. 1998; 6(Suppl 2):51S-209S.
38. US Department of Health and Human Services. Physical Activity and Health: A Report of the Surgeon General. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion; 1996.
39. Assmann G, Cullen P, Schulte H. The Münster Heart Study (PROCAM): results of follow-up at 8 years. Eur Heart J. 1998;19(Suppl A):A2-A11.
40. Eckel RH, Krauss RM, for the AHA Nutrition Committee. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. Circulation. 1998;97:2099-2100.
41. Felber JP, Golay A. Pathways from obesity to diabetes. Int J Obes. 2002;26(Suppl 2):S39-S45.
42. Lean ME. Pathophysiology of obesity. Proc Nutr Soc. 2000;59:331-336.
43. Astrup A, Finer N. Redefining type 2 DM: "diabesity" or "obesity dependent diabetes mellitus"? Obes Rev. 2000;1:57-59.
44. Burke JP, William; K, Gaskill SP, et al. Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: results from the San Antonio Heart Study. Arch Intern Med. 1999; 159:1450-1456.
45. Mokdad AH, Ford ES, Bowman BA, et al. The continuing increase of diabetes in the US. Diabetes Care. 2001;24:412.
46. Moore LL, Visioni AJ, Wilson PW, et al. Can sustained weight loss in overweight individuals reduce the risk of diabetes mellitus? Epidemiology. 2000;11:269-273.
47. Rubin RJ, Altman WM, Mendlson DN. Health care expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metab. 1994;78:809A-809E.
48. Harris MI, Zimmet P. Classification of DM Mellitus and Other Categories of Glucose Intolerance. International Textbook of Diabetes Mellitus. Chichester: John Wiley; 1992:3-18.
49. Felber J-P, Golay A. Pathways from obesity to diabetes. Int J Obes. 2002;26(Suppl 2): S29-S45.
50. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of not-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med. 1993;329:1988-1992.
51. Haffner S, Miettinen H, Gaskill S, et al. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes. 1995;44:1386-1391.
52. Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion vs impaired insulin sensitivity. Endocr Rev. 1998;19:491-503.
53. Polonsky K, Sturis J, Bell G. Noninsulin-dependent diabetes mellitus-a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med. 1996;334:777-783.
54. Mitrakou A, Kelley D, Veneman T, et al. Role of reduced suppression of hepatic glucose output and diminished early insulin release in impaired glucose tolerance. N Engl J Med. 1992;326:22-29.
55. Felber JP. From obesity to diabetes: pathophysiological considerations. Int J Obes. 1992; 16:937-952.
56. Felber J-P, Acheson KJ, Tappy L. From Obesity to Diabetes. Chichester: John Wiley; 1993.
57. Golay A, Munger R, Felber JP. Obesity and NIDDM: the retrograde regulation concept. Diabetes Rev. 1997;5:69-82.
58. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev. 1995; 75:473-486.
59. Gerich JE. The genetic basis of type 2 DM mellitus: impaired insulin secretion vs impaired insulin sensitivity. Endocr Rev. 1998;19:491-503.
60. Hamman RF. Genetic and environmental determinants of non-insulin- dependent diabetes mellitus (NIDDM). DM Metab Rev. 1992;8:287-338.
61. Yki-Järvinen H. Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia. 1995;38:1378-1388.
62. Zimmet PZ. The pathogenesis and prevention of diabetes in adults. Diabetes Care. 1995;18:1050-1064.
63. Chen YD, Golay A, Swislocki ALM, et al. Resistance to insulin suppression of plasma free fatty acid concentrations and insulin stimulation of glucose uptake in non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1987;64:17-21.
64. Baldeweg SE, Golay A, Natali A, et al. Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans. Eur J Clin Invest. 200;30:45-52.
65. Lônnqvist F, Thörne A, Nilsell K, et al. A pathogenic role of visceral fat β3-adrenoceptors in obesity. J Clin Invest. 1995;95:1109-1116.
66. Meylan M, Henny C, Temler E, et al. Metabolic factors in the insulin resistance in human obesity. Metabolism. 1987;36:256-261.
67. Shulman GI, Rothman DL, Jue T, et al. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes mellitus by 13C nuclear magnetic resonance spectroscopy. N Engl J Med. 1989;322:223-228.
68. Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest. 1999; 103:253-259.
69. Golay A, Felber JP, Meyer HU, et al. Study on lipid metabolism in obesity diabetes. Metabolism. 1984;33:111-116.
70. Felber JP, Ferrannini E, Golay A, et al. Role of lipid oxidation in pathogenesis of insulin resistance of obesity and type II diabetes mellitus. Diabetes. 1987;36:1341-1350.
71. Barak Y, Nelson MC, Ong ES, et al. PPAR-γ is required for placental, cardiac, and adipose tissue development. Mol Cell. 1999;4:585-595.
72. Rosen ED, Sarraf P, Troy AE, et al. PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell. 1999;4:611-617.
73. Willson TM, Brown PJ, Sternback DD, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000;43:527-550.
74. Yki-Järvinen H. Drug therapy: thiazolidinediones. N Engl J Med. 2004;351:1106-1118.
75. Desergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev. 1999;20:649-688.
76. Duez H, Chao YS, Hernandez M, et al. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem. 2002;277: 48051-48057.
77. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410-418.
78. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 DM: the DM Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905-910.
79. Michalik L, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors beta/delta: emerging roles for a previously neglected third family member. Curr Opin Lipidol. 2003;14:129-135.
80. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem. 2001;70:341-367.
81. Dubois M, Pattou F, Kerr-Conte J, et al. Expression of peroxisome proliferator-activated receptor gamma (PPARγ) in normal human pancreatic islet cells. Diabetologia. 2000;43:1165-1169.
82. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307-312.
83. McTernan PG, Fisher FM, Valsamakis G, et al. Resistin an type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab. 2003;88:6098-6106.
84. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45:1661-1669.
85. Ibrahimi A, Teboul L, Gaillard D, et al. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol Pharmacol. 1994;46:1070-1076.
86. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferators- activated receptor-γ (PPAR-γ). J Biol Chem. 1995;270:12953-12956.
87. Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study: the Pioglitazone 001 Study Group. Diabetes Care. 2000;23:1605-1611.
88. Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 DM mellitus: a randomized, placebo-controlled study. Am J Med. 2001;111:10-17.
89. Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 DM. J Clin Endocrinol Metab. 2001;86:280-288.
90. Wolffenbuttel BH, Gomis R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulfonylurea therapy improves glycemic control in type 2 diabetic patients. Diabet Med. 2000;17:40-47.
91. Gale EA. Lessons from the glitazones: a story of drug development. Lancet. 2001;357: 1870-1875.
92. Nathan DM. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med. 2002;347:1342-1349.
93. DeFronzo RA, Goodman AM, Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:541-549.
94. Boyle PJ, King AB, Olansky L, et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther. 2002;24:378-396.
95. Khan MA, St Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care. 2002;25:708-711.
96. King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 2000;23;557.
97. LaCivita KA, Villarreal G. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. Curr Med Res Opin 2002;18:363-370.
98. Wurch T, Junquero D, Delhom A, et al Pharmacological analysis of wild-type α, γ and δ subtypes of the human peroxisome proliferator-activated receptor. Naunyn Schmiedebergs Arch Pharmacol. 2002;365:133-140.
99. Tack CJ, Smits P, Demacker PN, et al. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. DM Care. 1998;21:796-799.
100. Hirano T, Yoshimo G, Kazumi T. Troglitazone and small low-density lipoprotein in type 2 diabetes. Ann Intern Med. 1998;129:162-163.
101. Cominacini L, Young MM, Capriati A, et al. Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers. Diabetologia. 1997;40:1211-1218.
102. Cominacini L, Garbin U, Fratta PA, et al. Troglitazone reduces LDL oxidation and lowers plasma E-selectin concentration in NIDDM patients. Diabetes. 1998;41:130-133.
103. Olefsky JM. Insulin resistance. In: Porte D, Sherwin RS, eds. Ellember and Rifkin's Diabetes Mellitus: Theory and Practice, 5th ed. New Hyde Park, NY: Medical Examination Publishing Co; 1997:151-178.
104. Suter S, Nolam J, Wallace P, et al. Metabolic effects of a new oral hypoglycemic agent, CS-045, in non-insulin dependent diabetic subjects. Diabetes Care. 1992;15:193-203.
105. Sironi AM, Vichi S, Gastaldelli A, et al. Effects of troglitazone on insulin action and cardiovascular risk factors in patients with non-insulin-dependent diabetes. Clin Pharmacol Ther. 1997;62:194-202.
106. Maggs DG, Buchanan TA, Burant CF, et al. Metabolic effects of troglitazone monotherapy in type 2 DM mellitus: a randomized, double-blind placebo-controlled trial. Ann Inern Med. 1998;128:176-185.
107. Tontonoz P, Nagy L. Regulation of macrophage gene expression by peroxisome-proliferator-activated receptor gamma: implications for cardiovascular disease. Curr Opin Lipidol. 1999;10:485-490.
108. Law RE, Meehan WP, Xi XP, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 1996;98:1897-1905.
109. Li AC, Brown KK, Silvestre MJ, et al. Peroxisome proliferators-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000;106:523-531.
110. Shiomi M, Ito T. Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits. Atherosclerosis. 1999;142:345-353.
111. Minamikawa J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 1998;83:1818-1820.
112. Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 2001;86:3452-3456.
113. Minamikawa J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 1998;83:1818-1820.
114. Marx N, Libby P, Plutzky J. Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? J Cardiovasc Risk. 2001;8:203-210.
115. Barbier O, Torra IP, Duguay Y, et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2002:22:717-726.
116. Jagdip SS, Zoltan K, Hugh SM, et al. Effects of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol. 2004;24:930-934.
117. Marx N, Duez H, Fruchart JC, et al. Peroxisome proliferator-activated receptors and atherosclerosis: regulators of gene expression in vascular cells. Circ Res. 2004;94:1168-1178.
118. Satoh H, Tsukamoto K, Hashimoto Y, et al. Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells: a new possible role of PPARγ on vascular endothelial function. Biochem Biophys Res Commun. 1999;254:757-763.
119. Diep QN, Schiffrin EL. Increased expression of peroxisome proliferators-activated receptor-α and -γ in blood vessels of spontaneously hypertensive rats. Hypertension. 2001;38:249-254.
120. Law RE, Goetze S, Xi X-P, et al. Expression and function of PPARγ in rat and human vasculare smooth muscle cells. Circulation. 2000;101:1311-1318.
121. Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferators-activated receptor (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA. 1998; 95:7614-7619.
122. Diep QN, El Mabrouk M, Cohn JS, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats; role of peroxisome proliferators-activated receptor-γ. Circulation. 2002;105:2296-2302.
123. Calnek DS, Mazzella L, Roser S, et al. Peroxisome proliferators activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23:52-57.
124. Wang C-H, Ciliberti N, Li SH, et al. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage-a new paradigm in glitazone pleiotropy. Circulation. 2004;109:1392-1400.
125. de Dios ST, Bruemmer D, Dilley RJ, et al. Inhibitory activity of clinical thiazolidinedione peroxisome proliferators activating receptor-γ ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation. Circulation. 2003;107:2548-2550.
126. Haffner SM, Greenberg AS, Weston WM, et al. Effects of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 DM mellitus. Circulation. 2002;106:679-684.
127. Marx N, Imhof A, Froehlich J, et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation. 2003; 107:1954-1957.
128. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferators-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen level in non-diabetic coronary artery disease patients. J Am Coll Cardiol. 2003;41:1575-1763.
129. Kelly DP. PPARs of the heart. Circ Res. 2003;92:482-484.
130. Yoshioka S, Nishini H, Shiraki T, et al. Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism. 1993;42:75-80.
131. Kaufman LN, Peterson MM, DeGrange LM. Pioglitazone attenuates diet-induced hypertension in rats. Metabolism. 1995;44:1105-1109.
132. Ogihara T, Rakugi H, Ikegami H, et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens. 1995;8: 316-320.
133. Shimoyama M, Ogino K, Tanaka Y, et al. Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts. Diabetes. 1999;48:609-615.
134. Uchida K, Ogino K, Shimoyama M, et al. Acute hemodynamic effects of insulin-sensitizing agents in isolated perfused rat heart. Eur J Pharmacol. 2000;400:113-119.
135. 2+-sensitizing effect is involved in the positive inotropic effect of troglitazone. Br J Pharmacol. 2001;133:1307-1313.
136. Ghazzi MN, Perez JE, Antonucci TK, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes. 1997;46:433-443.
137. Sung BH, Izzo JL FR, Dandona P, et al. Vasodilatory effects of troglitazone improve blood pressure at rest and during mental stress in type 2 diabetes mellitus. Hypertension. 1999;34:83-88.
138. Ogino K, Furuse Y, Uchida K, et al. Troglitazone improves cardiac function in patients with congestive heart failure. Cardiovasc Drugs Ther. 2002;16:215-220.
139. Bogoyevitch MA, Gillespie-Brown J, Kettkrman AJ, et al. Stimulation of the stress-activated mitogen-activated protein kinase subfamilies in perfused heart: p38/RD mitogen-activated protein kinases are activated by ischemia/reperfusion. Circ Res. 1996;79:162-173.
140. Knight RJ, Buxton DB. Stimulation of c-jun kinase and mitogen-activated protein kinase by ischemia and reperfusion in the perfused rat heart. Biochem Biophys Res Commun. 1996;218:83-88.
141. Shimizu N, Yoshiyama M, Omura T, et al. Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats. Cardiovasc Res. 1998; 38:116-124.
142. Yin T, Sandhu G, Wolfrang CD, et al. Tissue-specific pattern of stress kinase activation in ischemic/reperfused heart and kidney. J Biol Chem. 1997;272:19943-19950.
143. Khandoudi N, Delerive P, Berrebi-Bertrand I, et al. Rosiglitazone, a peroxisome proliferator-activated receptor-γ, inhibits the Jun NH2-terminal kinase/activated protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes. 2002;51:1507-1514.
144. Liu LS, Tanaka H, Ishii S, et al. The new antidiabetic drug MCC-555 acutely sensitizes insulin signaling in isolated cardiomyocytes. Endocrinology. 1998;139:4531-4539.
145. Yue TL, Chen J, Bao W, et al. in vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activator receptor-γ agonist rosiglitazone. Circulation. 2001;104:2588-2594.
146. Wang C-H, Weisel RD, Liu PP, et al. Glitazones and heart failure: critical appraisal for the clinician. Circulation. 2003;107:1350-1354.
147. Richard BC, Asnani S, Desouza C, et al. Is weight gain inevitable with thiazolidinediones? Experience with very low calorie diets [Abstract]. Diabetes. 2002;51 (Suppl 2): A609.
148. Nakamura T, Funahashi T, Yamashita S, et al. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation: double-blind placebo-controlled trial. Diabetes Res Clin Pract. 2001;54:181-190.
149. Kelly IE, Han TS, Walsh K, et al. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care. 1999;22:288-293.
150. Carey DG, Cowin GJ, Galloway GJ, et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obes Res. 2002;10:1008-1015.
151. Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 2002;51:797-802.
152. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002;87:2787-2791.
153. Martens FM, Visseren FL, Lemay J, et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs. 2002;62:1463-1480.
154. Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24:1226-1232.
155. Kennedy FP. Do thiazolidinediones cause congestive heart failure? Mayo Clin Proc. 2003;78:1076-1077.
156. Hirsch IB, Kelly J, Cooper S. Pulmonary edema associated with troglitazone therapy [Letter]. Arch Intern Med. 1999;159:1811.
157. Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc. 2003;78:1088-1091.
158. Thomas ML, Lloyd SJ. Pulmonary edema associated with rosiglitazone and troglitazone. Ann Pharmacother. 2001;35:123-124.
159. Wooltorton E. Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. Can Med Assoc J. 2002;166:219.
160. Tang WHW, Francis GS, Hoogwerf BJ, et al. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol. 2003;41:1394-1398.
161. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108:2941-2948.